Skip to main content
For Healthcare Professionals
Specialty_banner

Specialty

Boehringer Ingelheim specialty pioneering science inspired by patients we won’t rest until we can give people the chance to live the life they want.

ILDTalks PPF in CTD-ILD EP.5: How do we keep patients on treatment with nintedanib?

26/03/2024  |  Author: Boehringer Ingelheim

Document ID: PC-TH-104593

Specialty

ILDPPF||ILDTalks PPF in iNSIP EP.1: iNSIP, what is it?
ILDPPF||ILDTalks PPF in iNSIP EP.2: How do we monitor patients with iNSIP?
ILDPPF||ILDTalks PPF in CTD-ILD EP.1: The importance of early referral for patients with CTD-ILD: a pulmonologists perspective
ILDPPF||ILDTalks PPF in iNSIP EP.3: What are the first line treatment options in iNSIP?
ILDPPF||ILDTalks PPF in iNSIP EP.4: How do we treat patients with iNSIP who develop PPF?
ILDPPF||ILDTalks PPF in iNSIP EP.5: How has nintedanib affected our treatment of patients?
ILDPPF||ILDTalks PPF in HP EP.1: Hypersensitivity pneumonitis: a distinct form of ILD?
ILDPPF||ILDTalks PPF in CTD-ILD EP.2: How do we monitor patients with CTD-ILD?
ILDPPF||ILDTalks PPF in HP EP.7: What does the future of HP treatment look like?
ILDPPF||ILDTalks PPF in CTD-ILD EP.3: Treatment of patients with PPF and CTD-ILD
ILDPPF||ILDTalks PPF in CTD-ILD EP.4: How does nintedanib fit in with background treatments for underlying CTDs?
ILDPPF||ILDTalks PPF in HP EP.2: Differentiation from IPF
ILDPPF||ILDTalks PPF in HP EP.3: What are the treatment options for HP?
ILDPPF||ILDTalks PPF in HP EP.4: How can we monitor for progression in our patients with HP
ILDPPF||ILDTalks PPF in HP EP.5: How do we treat fibrotic, progressive HP
ILDPPF||ILDTalks PPF in HP EP.6: Practical experience with nintedanib
ILDPPF||ILDTalks PPF in CTD-ILD EP.5: How do we keep patients on treatment with nintedanib?

RELATED CONTENT